BMS’ Sotyktu secures EC approval for psoriatic arthritis
Pharmaceutical Business Review
The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy.
pharminent
May 11, 2026 (Last updated: May 12, 2026)
Pharmaceutical Business Review
The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy.
